Anixa Biosciences (NASDAQ:ANIX) is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.
In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom. ADAPT is designed to generate biomarker signatures for early detection and monitoring of cancer and other diseases, with initial studies focusing on breast and ovarian malignancies. This platform seeks to deliver non-invasive, blood-based tests that can aid in disease stratification and treatment decisions.
Since its founding, Anixa has engaged with academic institutions, government agencies and strategic partners to support its preclinical and clinical programs. The firm has leveraged grants and collaborations to advance its SARS-CoV-2 vaccine into regulatory review and to expand its oncology candidates into Phase II development. Headquartered in San Jose, California, Anixa maintains operations across the United States and continues to establish partnerships to extend its global research footprint.
Under the leadership of a management team with extensive experience in biotechnology, oncology and vaccine development, Anixa Biosciences is focused on translating its innovative platforms into clinically meaningful products. The company’s multidisciplinary approach, encompassing both therapeutic and diagnostic divisions, aims to address unmet needs in cancer and infectious disease through precision immunology solutions.
